CRPS-RISE Outcomes Registry
A Prospective Longitudinal Outcomes Registry of Complex Regional Pain Syndrome Type 1 (CRPS-1) in Participants Treated With Neridronate in the CRPS-RISE Trial and/or Open-Label Extension (OLE)
The goal of this observational study is to learn about how well neridronate keeps working in the months after treatment. For 12 or up to 24 months while the registry is open participants will answer online survey questions about their CRPS pain, medication use or procedures done and how CRPS affects what they are able to do.
調査の概要
状態
詳細な説明
The primary objective of the registry is to evaluate the long-term effectiveness of IV neridronate across three outcome domains in participants who qualified in CRPS-RISE with early, warm CRPS-1 and a positive triple phase bone scan, following prior treatment with four infusions of neridronate 100 mg IV over approximately a 10-day period. The three outcome domains include, patient report of health status, CRPS-1 related clinical events, and disability status.
No neridronate treatment will be given as part of the registry and limited safety information will be collected. Participants will have received neridronate either through CRPS-RISE and/or through the Open Label Extension.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:CRPS-RiseRegistry
- 電話番号:877-834-5183
- メール:CRPS-RiseRegistry@iqvia.com
研究場所
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27703
- 募集
- CRPS-RISERegistry
-
コンタクト:
- CRPS-RiseRegistry CRPS-RiseRegistry
- 電話番号:877-834-5183
- メール:CRPS-RiseRegistry@iqvia.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The registry target population for provisional enrollment includes all participants in CRPS-RISE, the parent trial of the Registry. After the completion of the last participant's last visit in CRPS-RISE and the unblinding of the trial, the Enrolled Study Cohort will be participants confirmed to have completed a four-infusion course of neridronate. The Enrolled Study Cohort will also include participants in the Open Label Extension study.
説明
Inclusion Criteria:
-
Participants from CRPS-RISE
-
Completion of four infusions of IP (neridronate 100 mg over a ~ 10-day period [or the renally modified dosing, as applicable] or placebo) in CRPS-RISE .
-
Completed CRPS-RISE with a final trial visit at Week 6 (Visit 8) or later.
Participants who meet both criteria will be provisionally enrolled pending post-trial unblinding and be included in the Provisionally Enrolled Study Cohort.
After CRPS-RISE last patient last visit unblinding, only participants who meet the following neridronate exposure criterion #3 will continue in registry follow-up and be included in the Enrolled Study Cohort:
-
Completion of 4-infusions of neridronate 100 mg over approximately a 10-day period in CRPS-RISE.
-
-
Participants from the Open Label Extension (OLE)
- Completion of 4 infusions of neridronate 100 mg over approximately a 10-day period (or the renally modified dosing, as applicable) in the OLE.
- Completed OLE with a final trial visit at Week 6 (Visit 8) or later.
Exclusion Criteria:
There are no exclusion criteria.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_ONLY
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Provisionally Enrolled Study Cohort
Participants provisionally enrolled in the registry. (Note: Participants provisionally enrolled who do not meet this neridronate-exposure criterion will not continue registry follow-up.) |
|
Enrolled Study Cohort
Participants who have consented to participate and meet all inclusion criteria including confirmation of completing four infusions of neridronate. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from baseline to each registry assessment of average pain in the past 24 hours.
時間枠:Every 3 months from enrollment until up to 2 years after entry.
|
Average pain (24-hour recall) reported on an 11-point numeric rating scale. This is recorded every 90 days from entry. |
Every 3 months from enrollment until up to 2 years after entry.
|
|
Time to loss of benefit where benefit is 50% reduction in average pain intensity from baseline to Week 12 of the CRPS-RISE trial.
時間枠:Every 3 months from enrollment until up to 2 years after entry.
|
Each patient reported registry assessment of average pain in the past 24 hours will use an 11 point numeric rating scale. The analysis will be limited to participants who experienced benefit. Data will be summarized as Kaplan-Meier estimates. |
Every 3 months from enrollment until up to 2 years after entry.
|
|
Change from baseline to each registry assessment in CRPS Severity Score Self-Report (CSS-SR) total score and individual items.
時間枠:Every 3 months from entry to up to 24 months of participation.
|
The CSS-SR is designed as a patient self-report questionnaire to assess the severity of CRPS signs and symptoms using plain language to assess 13 concepts. |
Every 3 months from entry to up to 24 months of participation.
|
|
Change from baseline to each registry assessment in Patient Global Impression of Severity (PGI-S).
時間枠:Every 3 months from enrollment until up to 2 years after entry.
|
The 6-point PGI-S is an overall assessment of the participant's perception of the severity of their CRPS condition at the time of the assessment. Participants will respond to the question "How would you rate the symptoms of your CPRS at this time." Possible responses are scored from 0 to 5 representing none, minimal, mild, moderate, severe, very severe. |
Every 3 months from enrollment until up to 2 years after entry.
|
|
Change from baseline to each registry assessment in each of the Short Form 12 Health Survey (SF-12, Acute Version 2) domains, Physical Component Score (PCS), Mental Component Score (MCS), and individual items.
時間枠:Every 3 months from enrollment until up to 2 years after entry.
|
The SF-12 is a widely used measure of general health status used in observational studies across a broad range of disease areas. It is a shortened version of the SF-36 V2.0 and yields 8 domain scores and a Physical Component Summary and Mental Component Summary. Each domain score is calculated by transforming raw responses to a 0-100 scale, where higher scores indicate better health status. |
Every 3 months from enrollment until up to 2 years after entry.
|
|
Change from baseline to each registry assessment in Daily Sleep Interference Scale (DSIS) in the past 24 hours on an 11-point numeric rating scale.
時間枠:Every 3 months from enrollment until up to 2 years after entry.
|
The DSIS is a single-item scale that assesses "how much did your pain interfere with your sleep during the past 24 hours?" (0 = did not interfere; 10 = completely interfered |
Every 3 months from enrollment until up to 2 years after entry.
|
|
CRPS-1 Related Clinical Events during the 3 months preceding each registry assessment.
時間枠:Every 3 months from enrollment until up to 2 years after entry.
|
The CRPS-1 Treatment Checklist was developed for this registry to assess commonly used pharmacologic treatments (e.g., opioids, neuropathic pain agents, ketamine, NSAIDs, bisphosphonates, corticosteroids, and topicals),interventional procedures (e.g., spinal cord or dorsal root ganglion stimulation, peripheral nerve stimulation, stellate/lumbar sympathetic blocks, sympathetic ablation/sympathectomy, intrathecal pump implant, and Bier block), and non-invasive rehabilitation therapies (e.g., physical therapy, occupational therapy, mirror visual feedback, psychological therapies, scrambler therapies or acupuncture). Participants select all CRPS-related treatments used in the past 3 months. The checklist will also record participation in the open-label clinical trial and is intended for descriptive evaluation of long-term CRPS-1 treatments with a focus on resource intensive events. The outcome domain assesses the long-term effectiveness of neridronate through patient reports. |
Every 3 months from enrollment until up to 2 years after entry.
|
|
Disability Status
時間枠:Every 3 months from enrollment until up to 2 years after entry.
|
During the 3 months preceding each registry assessment the participant reported applying for or being on short-term disability, long-term disability, or workers compensation. As a binary endpoint, it will be summarized as frequencies and percentages. The domain assesses the long-term effectiveness of neridronate through patient reports of short-term disability, long-term disability, and workers compensation. |
Every 3 months from enrollment until up to 2 years after entry.
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Healthcare Use and Costs (Provisional)
時間枠:Every 3 months from enrollment until up to 2 years after entry.
|
The potential for inclusion of linked health care claims and electronic health record data will be enabled by having participants consent to tokenizing their identifying information. |
Every 3 months from enrollment until up to 2 years after entry.
|
協力者と研究者
捜査官
- 主任研究者:Joel Castellanos, MD、UCSD
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- AMBTX-01-R01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。